Citigroup
TCRT icon

Citigroup’s Alaunos Therapeutics TCRT Stock Holding History

Citigroup’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-393
Closed -$148K – 7330
2020
Q4 		$148K Hold
393
– – ﹤0.01% 5223
2020
Q3 		$148K Hold
393
– – ﹤0.01% 4832
2020
Q2 		$193K Hold
393
– – ﹤0.01% 5038
2020
Q1 		$144K Sell
393
-486
-55% -$251K ﹤0.01% 5020
2019
Q4 		$622K Buy
879
+27
+3% +$18.6K ﹤0.01% 4225
2019
Q3 		$547K Sell
852
-67
-7% -$53.1K ﹤0.01% 4255
2019
Q2 		$804K Buy
919
+332
+57% +$228K ﹤0.01% 3905
2019
Q1 		$339K Sell
587
-18
-3% -$7.53K ﹤0.01% 4581
2018
Q4 		$170K Buy
605
+74
+14% +$29.3K ﹤0.01% 5182
2018
Q3 		$255K Sell
531
-40
-7% -$17.1K ﹤0.01% 4990
2018
Q2 		$259K Buy
571
+204
+56% +$129K ﹤0.01% 4789
2018
Q1 		$216K Buy
367
+48
+15% +$29.9K ﹤0.01% 4889
2017
Q4 		$198K Buy
319
+84
+36% +$60.4K ﹤0.01% 5053
2017
Q3 		$216K Sell
235
-130
-36% -$115K ﹤0.01% 4931
2017
Q2 		$341K Buy
365
+162
+80% +$159K ﹤0.01% 4345
2017
Q1 		$193K Sell
203
-126
-38% -$117K ﹤0.01% 4681
2016
Q4 		$264K Buy
329
+219
+199% +$197K ﹤0.01% 5049
2016
Q3 		$93K Sell
110
-84
-43% -$67.5K ﹤0.01% 5248
2016
Q2 		$160K Sell
194
-78
-29% -$84.9K ﹤0.01% 4701
2016
Q1 		$303K Buy
272
+134
+97% +$137K ﹤0.01% 4681
2015
Q4 		$172K Sell
138
-45
-25% -$74.4K ﹤0.01% 4884
2015
Q3 		$248K Sell
183
-106
-37% -$175K ﹤0.01% 4329
2015
Q2 		$520K Buy
289
+288
+28,800% +$447K ﹤0.01% 3667
2015
Q1 		$1K Buy
+1
New +$1.48K ﹤0.01% 7076

Other funds holding TCRT

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Citigroup's TCRT Position: Q1 2026 in Review

Citigroup reduced its Alaunos Therapeutics (TCRT) stake by 99% in Q1 2026, selling an estimated $263 and leaving 1 share worth $3. The position accounts for ﹤0.01% of the portfolio, ranked #5816.

Citigroup first reported a position in TCRT in Q2 2013 and has held it in 45 quarters since. The position peaked at $3.04M in Q1 2021. 29 funds tracked by Wall St. Rank hold TCRT as of Q1 2026.

  • Citigroup held 1 share of Alaunos Therapeutics worth $3 as of Q1 2026.
  • Citigroup sold 88 Alaunos Therapeutics shares in Q1 2026, an estimated $263.
  • Alaunos Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5816 holding.
  • Citigroup first reported a position in Alaunos Therapeutics in Q2 2013 and has held it in 45 quarters since.
  • Citigroup's Alaunos Therapeutics position peaked at $3.04M in Q1 2021.
  • 29 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.